Zim Laboratories Ltd

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net profit of ₹4.40 crores for Q3 FY26 (October-December 2025), marking a dramatic turnaround from the ₹0.42 crore loss recorded in Q2 FY26. However, this sequential recovery, whilst impressive at first glance, reveals deeper structural concerns when viewed against year-on-year comparisons and margin pressures that continue to plague the ₹407 crore market capitalisation company.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 05 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into its performance and outlook.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Zim Laboratories Ltd has touched a new 52-week low of Rs.64.1 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics. Despite a modest recovery over the past two days, the stock remains considerably below its previous highs and continues to trail behind sector benchmarks.

Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 August 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation metrics reflecting ongoing challenges in its financial and operational performance. This shift highlights the company’s current standing amid a backdrop of subdued profitability and persistent negative results.

Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The stock has faced persistent headwinds, with recent assessment changes highlighting concerns across multiple performance parameters.

Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.

Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.

Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.

Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.